Atlas Trials

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Clinical trial NCT04811560 · RECRUITING

Trial details

NCT number
NCT04811560
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Acute Leukemia
Start date
2021-05-19
Primary completion
2027-02-26
Enrollment
420

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.